NEUROGENE INC (NGNE) Stock News

USA - NASDAQ:NGNE - US64135M1053 - Common Stock

34.26 USD

+1.12 (+3.38%)

Last: 10/31/2025, 4:02:08 PM

34.26 USD

0 (0%)

After Hours: 10/31/2025, 4:02:08 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NGNE Latest News, Press Relases and Analysis

All

Press Releases

22 days ago - By: Benzinga - Mentions: XTLB NXL GTBP PCSA ...

12 Health Care Stocks Moving In Thursday's Intraday Session

22 days ago - By: Neurogene Inc.

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

23 days ago - By: Neurogene Inc.

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

24 days ago - By: Benzinga - Mentions: XBI ALDX APLT BCAX

4 Biotech Stocks Seeing Explosive Momentum Gains

a month ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Neurogene Inc.

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

3 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Neurogene Inc.

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

5 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Yahoo Finance - Mentions: DNUT MDGL FLWS RKT

Short Report: Bears bite into Krispy Kreme after another weak earnings report

6 months ago - By: Neurogene Inc.

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

6 months ago - By: Neurogene Inc.

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

6 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Neurogene Inc.

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

7 months ago - By: Neurogene Inc.

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

7 months ago - By: Neurogene Inc.

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

8 months ago - By: Neurogene Inc.

Neurogene to Participate in Upcoming Conferences

9 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

9 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

9 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE